BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Subscribe To Our Newsletter & Stay Updated
